Compare Amphastar Pharmaceuticals Inc (AMPH) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while TotalEnergies SE trades at $86.9 (market cap $193.69B). The key difference: TotalEnergies SE is far larger — about 224.2× Amphastar Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TTE | |
|---|---|---|
Market Cap | $863.95M | $193.69B |
Sector | Health | Energy |
52-Week High | $30.81 | $93.60 |
52-Week Low | $16.87 | $57.39 |
Enterprise Value | $1.26B | $224.68B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
TotalEnergies (TTE) trades at $85.83, down 0.51% on the day, with a neutral technical signal. The stock shows attractive valuation metrics, including a P/E of 10.74 and P/S of 0.96, while recent earnings beat expectations in Q1 and Q2 2026. The company is actively reshaping its portfolio, acquiring Shell's European renewables business and developing the Cronos gas field in Cyprus. Cash flow improved in 2025, with net cash flow turning positive to $358 million after two years of outflows.
The outlook is supported by a strong analyst consensus, with a $94 price target and 57.6% buy ratings, but risks include declining revenue trends, legal challenges from climate litigation, and exposure to volatile energy markets. The stock offers a compelling value proposition with solid profitability and strategic investments in both traditional and renewable energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
